Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207504 · ClinicalTrials.gov registry record · Phase 1
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02207504 is a Phase 1 study of Castration-resistant Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants, below the 216-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02207504, a Phase 1 study of Castration-resistant Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Crizotinib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-08 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207504
The ClinicalTrials.gov registry entry for NCT02207504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 216-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT02207504 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02207504 about?
NCT02207504 is a clinical study titled "Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer". This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT02207504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-08. Estimated completion is 2022-01-03.
What conditions does trial NCT02207504 study?
This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT02207504?
The interventions under investigation include: Enzalutamide (DRUG), Crizotinib (DRUG).
Who is sponsoring clinical trial NCT02207504?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02207504 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RECRUITING · Phase 1
-
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
RECRUITING · Phase 1
-
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.